🩸 Real-world glycaemic + weight benefits of oral semaglutide in T2DM
🔥 Main in 3 points
- 12 months of oral semaglutide in GLP-1RA–naïve Dutch adults with T2DM led to an HbA1c reduction of −16 mmol/mol and a mean weight loss of −4.7 kg.
- 70% achieved individualized HbA1c targets; safety signals were not flagged.
- Benefits align with clinical trial evidence, confirming real-world effectiveness.
🧪 Context
Retrospective cohort, n=731 (GLP-1RA naïve). Data from the Dutch PHARMO Data Network. Up to 12 months’ follow-up. Primary outcomes: HbA1c, weight, lipid and BP changes.
📍 Practical significance
Oral semaglutide offers significant glycaemic and weight benefits matching injection trials. Useful for T2DM patients prioritizing oral therapy—expect similar effectiveness and safety.
🔗 Source — PubMed | Publisher
📊 Risk prediction for GI adverse events with semaglutide
🧾 Situation
Adults with T2DM starting semaglutide.
✅ Do
- Assess history of GI disorders before initiation.
- Screen for alcohol consumption.
- Review for concurrent α-glucosidase inhibitor use.
⚠️ With caution
- Recognize that ~19% may develop GI side effects.
- Risk increases substantially with the above risk factors (OR ~2–10 for GI disorders, ~1.3–6.6 for alcohol, ~1.4–6.5 for α-glucosidase inhibitor).
🚫 Avoid
- Ignoring comorbid GI conditions or concomitant medications known to up GI risk.
🔗 Source — PubMed | Publisher
🫀 Low-dose semaglutide improves HFpEF remodeling—independent of weight loss
❓ Practice question
Can low-dose semaglutide benefit HFpEF irrespective of weight loss?
✅ Study answer
In obese HFpEF-prone rats, low-dose semaglutide (30 nmol/kg, 16 weeks) improved cardiac function, exercise tolerance, and reduced cardiac/hepatic fibrosis—without weight loss. Multi-omics showed reduced tissue lipid, pro-fibrotic/hypertrophic signals, and systemic inflammation.
📍 How to apply
Consider GLP-1RA benefits in HFpEF even at low doses/without weight change; clinical trials in non-obese or lower-dose strategies may be justified. Monitor functional and metabolic cardiac signals, not just anthropometrics.
🔗 Source — PubMed | Publisher
⚖️ Semaglutide outperforms dulaglutide and liraglutide in Chinese T2DM: real-world data
🔥 Main in 3 points
- Semaglutide 1 mg beat dulaglutide 1.5 mg and liraglutide 1.8 mg for HbA1c reduction (−0.27% and −0.39%, respectively; p = 0.008/ < 0.001) and glycaemic target achievement.
- Real-world, multicenter, propensity-matched; n>100 per group.
- Safety was similar across all groups.
🧪 Context
Chinese adults with T2DM, real-world clinics, head-to-head effectiveness and safety.
📍 Practical significance
If available, semaglutide should be preferred for better glycaemic outcomes. Equivalent safety expected. Provides confidence for East Asian populations.
🔗 Source — PubMed | Publisher
🧠 Semaglutide plus bimagrumab: tackling lean mass loss in obesity therapy
🫀 Title
Combination therapy with bimagrumab and semaglutide may mitigate lean body mass loss associated with GLP-1RA-induced weight reduction.
🧪 What was studied
Review of clinical and mechanistic data on bimagrumab, a myostatin/activin II receptor blocker, for muscle preservation—alone and with semaglutide (and vs. dual incretin drugs).
📈 Key results
Bimagrumab increases lean body mass; when combined with semaglutide in obesity/T2DM, it preserves muscle while supporting fat loss. Up to 40% of semaglutide-induced weight loss may be lean mass if used alone.
📍 What this changes in practice
Consider risk of sarcopenia in aggressive GLP-1RA–mediated weight loss. Dual therapy with bimagrumab may become relevant for older, frail, or sarcopenic patients—await more outcome data.
🔗 Source — PubMed | Publisher
🔄 Additive effect: NLRP3 inhibition + semaglutide for metabolic inflammation
🧪 What was studied
In obese male mice, NLRP3 inflammasome inhibitor VTX3232 reduced inflammation, weight, glucose, and hepatic steatosis. When combined with semaglutide, additive improvements were observed.
📈 Key results
In vivo: Combination superior to either agent for reducing inflammatory markers, weight, glycemia, and hepatic steatosis. No impact in lean mice (specific to metabolic inflammation context).
📍 What this changes in practice
Future therapies in obesity/NAFLD may pair NLRP3 blockers with GLP-1RA for greater effect—especially in patients with prominent inflammatory or liver components.
🔗 Source — PubMed | Publisher
🩸 Semaglutide in Japanese T2DM—ORIGAMI real-world outcomes
🧪 What was studied
Retrospective multicenter RWD, n=503 Japanese adults with T2DM, semaglutide weekly. 52-week outcomes for HbA1c, weight, lipids, liver/kidney function, GI AEs.
📈 Key results
Mean HbA1c fell ~0.9%; weight −4.3 kg at 52 weeks; lipid/liver function improved. GI side effects in 53.7% (most mild); 7.6% discontinued due to these.
📍 What this changes in practice
Semaglutide is robustly effective and safe in Japanese T2DM, with slightly higher GI AE rates—but mirroring trial data. Expect more pronounced benefits in GLP-1RA–naïve, higher BMI, or raised ALT patients.
🔗 Source — PubMed | Publisher
|
